UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

Leukemia, 2011-11, Vol.25 (11), p.1751-1759

2011

Volltextzugriff (PDF)

MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist

Journal of medicinal chemistry, 2005-11, Vol.48 (22), p.6970-6979

2005

Volltextzugriff (PDF)

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

Leukemia, 2012-02, Vol.26 (2), p.236-243

2012

Volltextzugriff (PDF)

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Blood cancer journal (New York), 2012-05, Vol.2 (5), p.e69-e69

2012

Volltextzugriff (PDF)

Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours

Annals of oncology, 2018-11, Vol.29, p.ix23-ix24

2018

Volltextzugriff (PDF)

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

Annals of oncology, 2011-11, Vol.22 (11), p.2516-2522

2011

Volltextzugriff (PDF)

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer

Molecular cancer therapeutics, 2010-03, Vol.9 (3), p.642-652

2010

Volltextzugriff (PDF)

71OPhase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours

Annals of oncology, 2016-12, Vol.27, p.ix47-ix47

2016

Volltextzugriff (PDF)

PP72 Demonstration of dose-dependent target inhibition using a quantitative biomarker assay for SB939, a potent, orally active HDAC inhibitor, in a Phase I clinical study in solid tumors

European journal of cancer supplements, 2009, Vol.7 (4), p.26-26

2009

Volltextzugriff (PDF)

KINETIC MODELING OF TRANSESTERFICATION REACTION FOR BIODIESEL PRODUCTION USING HETEROGENEOUS CATALYST

International journal of engineering science and technology, 2011-04, Vol.3 (4), p.3463-3463

2011

Volltextzugriff (PDF)

413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies

European journal of cancer supplements, 2008, Vol.6 (12), p.130-130

2008

Volltextzugriff (PDF)

83 POSTER A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor

European journal of cancer supplements, 2008, Vol.6 (12), p.28-29

2008

Volltextzugriff (PDF)

Liquid−Liquid Equilibria for the Cyclohexane + Benzene + Dimethylformamide + Ethylene Glycol System

Journal of chemical and engineering data, 1998-11, Vol.43 (6), p.925-927

1998

Volltextzugriff (PDF)

Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.2560-2560

2009

Volltextzugriff (PDF)

166 POSTER ADME and PK/PD attributes of SB939, a potent orally active HDAC inhibitor

European journal of cancer supplements, 2006-11, Vol.4 (12), p.53-53

2006

Volltextzugriff (PDF)

MoO3–x Nanowire Arrays As Stable and High-Capacity Anodes for Lithium Ion Batteries

Nano letters, 2012-04, Vol.12 (4), p.1784-1788

2012

Volltextzugriff (PDF)

MoO 3– x Nanowire Arrays As Stable and High-Capacity Anodes for Lithium Ion Batteries

Nano letters, 2012-04, Vol.12 (4), p.1784-1788

2012

Volltextzugriff (PDF)

Kinetically limited de-lithiation behavior of nanoscale tin-covered tin oxide nanowires

Energy & environmental science, 2011-01, Vol.4 (5), p.1695-1699

2011

Volltextzugriff (PDF)

In Vitro Phase I Cytochrome P450 Metabolism, Permeability and Pharmacokinetics of SB639, a Novel Histone Deacetylase Inhibitor in Preclinical Species

Biological and Pharmaceutical Bulletin, 2007, Vol.30(5), pp.1021-1024

2007

Volltextzugriff (PDF)

MoO sub(3-x) Nanowire Arrays As Stable and High-Capacity Anodes for Lithium Ion Batteries

Nano letters, 2012-04, Vol.12 (4), p.1784-1788-1784-1788

2012

Volltextzugriff (PDF)

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults

Infectious diseases and therapy, 2022-10, Vol.11 (5), p.1999-2015

2022

Volltextzugriff (PDF)

Combined advanced oxidation and biological treatment of tannery effluent

Clean technologies and environmental policy, 2012-04, Vol.14 (2), p.251-256

2012

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(31)
Buchkapitel
(1)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Life Sciences & Biomedicine
(10)
Humans
(6)
Oncology
(5)
Pharmacokinetics
(5)
Biological And Medical Sciences
(4)
Female
(4)
Medical Sciences
(4)
Administration, Oral
(3)
Animals
(3)
Chemistry
(3)
Hematology
(3)
Hematology, Oncology And Palliative Medicine
(3)
Mice
(3)
Mice, Inbred Balb C
(3)
Science & Technology - Other Topics
(3)
Technology
(3)
Aml
(2)
Animal Models
(2)
Antineoplastic Agents - Pharmacology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer

71OPhase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours

152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours

152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours

PP72 Demonstration of dose-dependent target inhibition using a quantitative biomarker assay for SB939, a potent, orally active HDAC inhibitor, in a Phase I clinical study in solid tumors

KINETIC MODELING OF TRANSESTERFICATION REACTION FOR BIODIESEL PRODUCTION USING HETEROGENEOUS CATALYST

413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies

83 POSTER A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor

Liquid−Liquid Equilibria for the Cyclohexane + Benzene + Dimethylformamide + Ethylene Glycol System

Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies

166 POSTER ADME and PK/PD attributes of SB939, a potent orally active HDAC inhibitor

MoO3–x Nanowire Arrays As Stable and High-Capacity Anodes for Lithium Ion Batteries

MoO 3– x Nanowire Arrays As Stable and High-Capacity Anodes for Lithium Ion Batteries

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

Kinetically limited de-lithiation behavior of nanoscale tin-covered tin oxide nanowires

In Vitro Phase I Cytochrome P450 Metabolism, Permeability and Pharmacokinetics of SB639, a Novel Histone Deacetylase Inhibitor in Preclinical Species

MoO sub(3-x) Nanowire Arrays As Stable and High-Capacity Anodes for Lithium Ion Batteries

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults

Combined advanced oxidation and biological treatment of tannery effluent

Suchergebnisse filtern